Robeco Institutional Asset Management B.V. lowered its stake in shares of C.R. Bard, Inc. (NYSE:BCR) by 89.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,430 shares of the medical instruments supplier’s stock after selling 101,736 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in C.R. Bard were worth $3,611,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. ClariVest Asset Management LLC acquired a new position in shares of C.R. Bard during the first quarter valued at about $148,000. SRS Capital Advisors Inc. increased its holdings in shares of C.R. Bard by 0.7% during the first quarter. SRS Capital Advisors Inc. now owns 598 shares of the medical instruments supplier’s stock valued at $148,000 after acquiring an additional 4 shares in the last quarter. Parallel Advisors LLC increased its holdings in shares of C.R. Bard by 283.8% during the first quarter. Parallel Advisors LLC now owns 499 shares of the medical instruments supplier’s stock valued at $153,000 after acquiring an additional 369 shares in the last quarter. Bronfman E.L. Rothschild L.P. increased its holdings in shares of C.R. Bard by 16.7% during the first quarter. Bronfman E.L. Rothschild L.P. now owns 788 shares of the medical instruments supplier’s stock valued at $196,000 after acquiring an additional 113 shares in the last quarter. Finally, Penserra Capital Management LLC increased its holdings in shares of C.R. Bard by 9.5% during the first quarter. Penserra Capital Management LLC now owns 828 shares of the medical instruments supplier’s stock valued at $205,000 after acquiring an additional 72 shares in the last quarter. Hedge funds and other institutional investors own 79.34% of the company’s stock.

Shares of C.R. Bard, Inc. (NYSE BCR) opened at 320.04 on Monday. C.R. Bard, Inc. has a 12 month low of $203.63 and a 12 month high of $323.27. The company has a 50-day moving average price of $320.05 and a 200-day moving average price of $292.36. The stock has a market cap of $23.26 billion, a price-to-earnings ratio of 42.02 and a beta of 0.60.

C.R. Bard (NYSE:BCR) last announced its earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share for the quarter, beating the consensus estimate of $2.84 by $0.08. C.R. Bard had a return on equity of 48.70% and a net margin of 14.99%. The company had revenue of $979.70 million for the quarter, compared to the consensus estimate of $976.53 million. During the same period last year, the business posted $2.54 EPS. The company’s revenue was up 5.2% on a year-over-year basis. On average, analysts expect that C.R. Bard, Inc. will post $11.84 EPS for the current fiscal year.

Several research firms have recently issued reports on BCR. BidaskClub downgraded shares of C.R. Bard from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Jefferies Group LLC reiterated a “hold” rating on shares of C.R. Bard in a research report on Thursday, August 3rd. Zacks Investment Research lowered C.R. Bard from a “buy” rating to a “hold” rating in a research report on Tuesday, August 1st. Finally, BMO Capital Markets reiterated a “hold” rating and issued a $317.00 target price on shares of C.R. Bard in a research report on Tuesday, July 11th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, one has given a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $285.67.

TRADEMARK VIOLATION NOTICE: “C.R. Bard, Inc. (BCR) Stake Lessened by Robeco Institutional Asset Management B.V.” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/09/04/c-r-bard-inc-bcr-stake-lessened-by-robeco-institutional-asset-management-b-v.html.

In other C.R. Bard news, insider John P. Groetelaars sold 23,687 shares of C.R. Bard stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $318.73, for a total value of $7,549,757.51. Following the transaction, the insider now directly owns 31,445 shares in the company, valued at approximately $10,022,464.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.80% of the company’s stock.

C.R. Bard Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Stock Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related stocks with our FREE daily email newsletter.